Overall rank by patents
#49,382
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 7 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Orlucent ranks #49,382 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 7 technology areas.
USPTO PatentsView assignee plate
Corpus R49382 · US Corporation #49,382 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Oribase Pharma (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Beijing Bio-targetin… · near
29 score
Nevis Industries · near
29 score
Nvidia Technology UK · near
29 score
Orlucent · this assignee
29 score
Unitract Syringe PTY · near
29 score
3D Lighting… · lowest
7 score
What this shows Orlucent's Innovation Score is 29.0/100 (29th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Orlucent Inc. is a focused PatentsView assignee: 7 CPC subclasses with 80% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, Orlucent sits between Oribase Pharma and Osang Healthcare Co., Ltd..
Orlucent Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Oribase Pharma
5 patents
Orient Service Co., Ltd.
5 patents
Orion Biotech Inc.
5 patents
Orion Innovations Inc.
5 patents
Orthogen AG
5 patents
Ortlieb Sportarikel GMBH
5 patents
Oryza OIL & FAT Chemical Co., Ltd.
5 patents
Osang Healthcare Co., Ltd.
5 patents
Orlucent Inc.
5 patents
What this shows Orlucent holds 5 patents at rank #49,309, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #49,309 in granted patent volume.
Other assignees with the most granted patents in Orlucent's primary technology class.
Two PlainPatent-derived peer sets for Orlucent, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (29 here).
Orlucent's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 29th percentile higher than 29% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 20.0% |
| 2020 | 1 | 20.0% |
| 2021 | 1 | 20.0% |
| 2023 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
Top 7 of 7 technology areas
Overall rank by patents
#49,382
of 49,997 tracked assignees
29.0 out of 100
What to do with this data
Orlucent Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.